Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2012, XXXII/190: 260-262 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2012, XXXII/190: 260-262

Title: Calcimimetic drugs in stage 3–5 chronic kidney disease

Authors: Grzegorzewska A.E., Niepolski L.

More details

11/190

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Calcimimetic drugs in stage 3–5 chronic kidney disease


Grzegorzewska A.E.1, Niepolski L.2

1Karol Marcinkowski University of Medical Sciences in Poznań, Poland, Chair and Department of Nephrology, Transplantology and Internal Diseases; 2B/Braun Avitum Poland, Dialysis Center, Nowy Tomyśl

This review is focused on results of application of calcimimetic drug – cinacalcet in the treatment of secondary hyperparathyroidism in patients in 3–5 stage chronic kidney disease (CKD), excluding dialysis patients (stage 5D CKD). Oral administration of cinacalcet (15–180 mg/day) significantly reduced plasma parathormone (PTH) concentrations (30% as compared to the baseline values), but simultaneously side effects occurred, among them hypocalcemia and hyperphosphatemia. Hypocalcemia was a reason for cinacalcet withdrawal in 2–15% of patients. There is a lack of studies showing the influence of advantages and disadvantages of long-term administration of cinacalcet on outcome of 3–5 stage CKD patients.

Key words: cinacalcet, chronic kidney disease, side effects

Pol. Merk. Lek., 2012, XXXII, 190, 260